*I agree that it’s ridiculous to ask for $35k if the drug you’re researching is the world-changing COVID therapeutic.* Sorry but I do not think you know what you talk about in the affaires of Ipix.
You’re forgetting that the RBL already said BrilAcidin is worth continued testing and, with IPIX, applied for a grant to that end. And, further, plans to publish the peer reviewed results from their work.
Hardly..."I agree that it’s ridiculous to ask for $35k if the drug you’re researching is the world-changing COVID therapeutic."
its a government/grant funded RBL...they work only on matters for which they are funded...as Leo stated $35k funding "costs" for additional research/testing outside RBL scope originally tasked for...was a bargain...the results of which imo will be invaluable and learned shortly
Grumpy...only thing ridiculous..and out of order are your conclusions/statements
Brilacidin might be a line item with many other therapeutics however where are all the other GMU announcements that those other drugs have advanced to obtaining the ec50 values? Hmmmmmm. I cant find any other drug being researched in this fashion at gmu. Remember this was not an ipix pr but rather a GMU announcement longs came across.